Myasthenia Gravis - FOI Response Register

1. The number of patients with generalised Myasthenia Gravis (gMG) treated in each month for January, February, March, April, May, and June 2024

NHS Shetland uses the ICD 10 coding system. Figures provided are for the number of inpatients where ICD 10 code G70.0 Myasthenia Gravis was listed as Main Condition or Other Condition.

Where we have given <5 answers, this is because NHS Shetland considers that providing more specific information carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.

2. The volume of medication dispensed and/or consumed in each month for January, February, March, April, May, and June 2024 for each of the products below for gMG patients. If it is more convenient to specify the number of vials, pre-filled syringes, or tablets, that would also be very helpful.

• Steroids

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested. Steroids are used for many indications and we do not keep information that enables us to answer this question.

• Acetylcholinerase Inhibitors (ACHEis)

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested. Acetylcholinesterase inhibitors are used for many indications and we do not keep information that enables us to answer this question.

• Immunosuppressants

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested. Immunosuppressants are used for many indications and we do not keep information that enables us to answer this question.

• Anti-CD20 – Rituximab - 0
• Immunoglobulins - 0
• Anti-FcRn – 0
• Complement Inhibitors -0